The “Warnings and Precautions” section of the product prescribing information for enzalutamide (Xtandi) includes the following statement: Seizure occurred in 0.5% of patients receiving XTANDI. In patients with predisposing factors, seizures were reported in 2.2% of patients. Permanently discontinue XTANDI in patients who develop a seizure during treatment. However, the developers of enzalutamide have long […]
↧